ACADIA Pharmaceuticals Inc.
NASDAQACADIA Pharmaceuticals enters the back half of September with short interest climbing sharply back toward levels that dominated the stock through most of August, even as the borrow market remains extraordinarily loose — a split that sets up an interesting read on how aggressive the bears really are. The most notable move this week is in short interest itself. Shares short jumped…
ACAD short interest plunges 18% in one day to 5.3% of float, a dramatic reversal after analysts raised price targets to $34–$49.
ACADIA Pharmaceuticals enters the back half of September with short interest climbing sharply back toward levels that dominated the stock through most of August, even as the borrow market remains extraordinarily loose…
Short sellers are retreating from ACAD at an unusual pace. Short interest fell 18% in a single session on August 26, dropping to 5.3% of free float — down 21% on the week and 14% over the past month. The trigger is…
Snapshot as of 20 Sept 2026
ACAD enters its August 6 earnings report with the Street raising targets on the same day the stock gained 6%, a rare confluence that sharpens the focus on what management says next. The analyst moves this week tell a…
ACAD heads into its August 6 earnings report with bears in full retreat and options traders positioned firmly on the bullish side. The most striking shift in the setup is the dramatic unwind of short positions. Short…
ACADIA Pharmaceuticals enters the week of its earnings release with short interest at a four-month high — up 25% in just one month — yet the borrow market remains so loose it barely registers as friction. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ACAD — free to start on ORTEX.
Sign up for free →Open ACAD on ORTEX